For semaglutide, the NIH LiverTox record says serum enzyme elevations in large trials were no more common than with placebo, and a 72-week phase 2 trial in NASH found resolution in 59% of patients on daily semaglutide 0.4 mg versus 17% on placebo (n=320; NEJM 2021). LiverTox scores semaglutide likelihood D: a possible but very rare cause of clinically apparent liver injury. Most unregulated research peptides have no liver-panel data at all.
How the liver handles peptides
Peptides are chains of amino acids, and the body breaks them down the way it breaks down dietary protein: enzymes called peptidases cleave them into fragments and free amino acids. Unlike many small-molecule drugs, most therapeutic peptides are not cleared through the liver's cytochrome P450 enzyme system — the pathway responsible for a large share of classic drug-induced liver injury and drug–drug interactions.
That pharmacology is one reason peptide drugs, as a class, are not prominent causes of hepatotoxicity. It is not a guarantee. Any injected compound can trigger immune reactions, and a peptide that changes appetite, body weight, or metabolism can change liver enzymes indirectly — in either direction.
What approved peptide medicines show in trials
Semaglutide (the GLP-1 receptor agonist in Ozempic and Wegovy) is the most closely watched example, because millions of people use it. The NIH's LiverTox reference — the standard catalog of drug-induced liver injury — reports that in large clinical trials, serum enzyme elevations were no more common with semaglutide than with placebo, and that treatment was usually associated with improvements in aminotransferase (ALT/AST) levels and hepatic steatosis. LiverTox assigns semaglutide a likelihood score of D: a possible but very rare cause of clinically apparent liver injury, based on a small number of post-marketing case reports rather than any signal in trials.
This is what a characterized risk profile looks like: tens of thousands of trial participants, routine liver-panel monitoring, and a pharmacovigilance system that catches even single-digit case counts after launch.
Some peptides are being studied as liver treatments
The relationship can run the other way: fatty liver disease is a major research target for peptide drugs. In a 72-week phase 2 trial in nonalcoholic steatohepatitis (NASH), daily semaglutide 0.4 mg produced NASH resolution in 59% of patients versus 17% on placebo (n=320, NEJM 2021), largely tracking the weight loss it produced. So the question "do peptides affect the liver" has a genuinely two-sided answer: the best-evidenced effects of GLP-1 peptides on the liver are beneficial ones.
How liver safety is monitored in trials and practice
Formal drug development watches a standard set of hepatic signals:
- ALT and AST (aminotransferases) — enzymes released when liver cells are injured.
- Alkaline phosphatase and bilirubin — markers of bile-flow problems and overall liver function.
- Combined patterns — a rising ALT together with rising bilirubin ("Hy's law" cases) is the red flag regulators treat most seriously.
Trial protocols check these at baseline and on a schedule, exclude or stratify people with significant pre-existing liver disease, and report abnormalities in the label. That monitoring infrastructure is precisely what does not exist around gray-market peptide use.
The evidence gap for research peptides
For compounds like BPC-157, AOD-9604, or 5-amino-1MQ, there are no large human trials, no liver-panel datasets, and no post-marketing surveillance. When the FDA reviewed several of these substances for compounding, it concluded it had "no, or only limited, safety-related information" for compounds including BPC-157 — along with concerns about peptide-related impurities and immunogenicity. An absence of reported liver injury from a compound nobody has systematically monitored is not evidence of hepatic safety; it is evidence of an unmonitored compound.
Product quality adds a second, separate hazard: an unregulated vial can contain the wrong dose, residual synthesis impurities, or contaminants — exposures that have nothing to do with the peptide's own biology but still reach the liver.